Copyright
©The Author(s) 2020.
World J Clin Oncol. Dec 24, 2020; 11(12): 1018-1028
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1018
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1018
Table 1 Baseline characteristics of breast cancer patients
Variables | Levels | Total, n % |
Age | mean ± SD | 48.28 ± 11.83 |
Region | Punjab | 88 (88.0%) |
Khyber Pakhtunkhwa | 7.0 (7.0%) | |
Kashmir | 3.0 (3.0%) | |
Sindh | 2.0 (2.0%) | |
Histology | Ductal | 91 (91.0%) |
Others | 9.0 (9.0%) | |
Grade | II | 35 (35.0%) |
III | 56 (56.0%) | |
UNK | 09 (9.0%) | |
Tumor size | T1 | 7.0 (7.0%) |
T2/T3 | 57 (57.0%) | |
UNK | 36 (36.0%) | |
Nodes | Negative | 37 (37.0%) |
Positive | 50 (50.0%) | |
UNK | 13 (13.0%) | |
Metastasis | Negative | 38 (38.0%) |
Positive | 49 (49.0%) | |
UNK | 13 (13.0%) | |
Estrogen receptor | Negative | 69 (69.0%) |
Positive | 31 (31.0%) | |
Progesterone receptor | Negative | 74 (74.0%) |
Positive | 26 (26.0%) | |
HER2 status | Negative | 74 (74.0%) |
Positive | 26 (26.0%) | |
TNBC | No | 51 (51.0%) |
Yes | 49 (49.0%) | |
Status | Alive | 50 (50.0%) |
Death | 35 (35.0%) | |
Lost to follow-up | 15 (15.0%) | |
FOXP3 | Negative | 75 (75.0%) |
Positive | 25 (25.0%) | |
IDO score | Low | 24 (24.0%) |
Medium | 27 (27.0%) | |
High | 49 (49.0%) |
Table 2 Comparative characteristics of triple negative breast cancer and hormone positive breast cancer patients
Variables | Levels | Triple negative breast cancer, n (%) | Hormone positive breast cancer, n (%) |
Age | mean ± SD | 47.24 ± 11.5 | 49.27 ± 12.0 |
Histology | Ductal | 46 (50.5) | 45 (49.5) |
Others | 3 (33.3) | 6 (66.7) | |
Total | 49 (49.0) | 51 (51.0) | |
Grade | II | 9 (25.7) | 26 (74.3) |
III | 37 (66.1) | 19 (33.9) | |
UNK | 3 (33.3) | 6 (66.7) | |
Total | 49 (49.0) | 51 (51.0) | |
Tumor size | T1 | 4 (57.1) | 3 (42.9) |
T2/T3 | 26 (45.6) | 31 (54.4) | |
UNK | 19 (52.8) | 17 (47.2) | |
Total | 49 (49.0) | 51 (51.0) | |
Nodes | Negative | 23 (62.1) | 14 (37.8) |
Positive | 21 (42.0) | 29 (58.0) | |
UNK | 5 (38.4) | 8 (61.6) | |
Total | 49 (49.0) | 51 (51.0) | |
Metastasis | Negative | 23 (60.5) | 15 (39.5) |
Positive | 21 (42.8) | 28 (57.2) | |
UNK | 5 (38.4) | 8 (61.6) | |
Total | 49 (49.0) | 51 (51.0) |
Table 3 Clinicopathological characteristics of breast cancer patients with nuclear forkhead box P3 expression
Case | Histology | Age in yr | Grade | Nodes | Metastasis | ER | PR | HER2 | TNBC |
1 | Ductal | 28 | 3 | 0 | - | - | - | - | + |
2 | Ductal | 54 | 3 | 14 | + | - | - | - | + |
3 | Ductal | 67 | 3 | 1 | + | - | - | - | + |
4 | Ductal | 65 | 2 | UNK | UNK | - | - | - | + |
5 | Ductal | 45 | 3 | 13 | + | - | - | - | + |
6 | Ductal | 45 | 3 | 0 | - | - | - | - | + |
7 | Ductal | 55 | 3 | 0 | - | - | - | - | + |
8 | Ductal | 23 | 3 | 0 | - | - | - | - | + |
9 | Ductal | 47 | 2 | 0 | - | - | - | - | + |
10 | Ductal | 73 | 3 | 2 | + | - | - | - | + |
11 | Ductal | 35 | 3 | 0 | - | - | - | - | + |
12 | Ductal | 35 | 3 | 0 | - | - | - | - | + |
13 | Ductal | 52 | 3 | UNK | UNK | - | - | - | + |
14 | Ductal | 39 | 3 | 0 | - | - | - | - | + |
15 | Ductal | 48 | 3 | 0 | - | - | - | - | + |
16 | Ductal | 70 | 3 | 2 | + | - | - | - | + |
17 | Ductal | 40 | 3 | 13 | + | - | - | - | + |
18 | Ductal | 35 | 3 | 13 | + | - | - | - | + |
19 | Ductal | 43 | 3 | 0 | UNK | - | - | + | - |
20 | Ductal | 36 | 2 | 1 | + | - | - | + | - |
21 | Ductal | 45 | 3 | UNK | UNK | + | + | - | - |
22 | Ductal | 71 | 2 | 6 | + | + | - | - | - |
23 | Ductal | 30 | 2 | 17 | + | + | + | - | - |
24 | Ductal | 40 | 2 | UNK | UNK | - | - | + | - |
25 | Ductal | 62 | 2 | 0 | - | + | + | + | - |
Table 4 Patients and tumor characteristics of forkhead box P3 negative vs positive
Variables | Characteristics | FOXP3 negative 75 (75.0%) | FOXP3 positive 25 (25.0%) | P value |
Age (yr) | mean ± SD | 48.60 ± 11.02 | 47.32 ± 14.20 | 0.64 |
IDO score | Low | 22 (91.7%) | 2 (8.3%) | 0.01a |
Medium | 23 (85.2%) | 4 (14.8%) | ||
High | 30 (61.2%) | 19 (38.8%) | ||
Grade | II | 28 (80.0%) | 7 (20.0%) | 0.21 |
III | 38 (67.9%) | 18 (32.1%) | ||
Metastasis | Negative | 27 (71.1%) | 11 (28.9%) | 0.45 |
Positive | 39 (79.6%) | 10 (20.4%) | ||
Tumor size | T1 | 4 (57.1%) | 3 (42.9%) | 0.15 |
T2/T3 | 46 (80.7%) | 11 (19.3%) | ||
Lymph nodes involvement | Negative | 26 (70.3%) | 11 (29.7%) | 0.29 |
Positive | 40 (80.0%) | 10 (20.0%) | ||
Estrogen receptor | Negative | 48 (69.6%) | 21 (30.4%) | 0.06 |
Positive | 27 (87.1%) | 4 (12.9%) | ||
Progesterone receptor | Negative | 52 (70.3%) | 22 (29.7%) | 0.06 |
Positive | 23 (88.5%) | 3 (11.5%) | ||
HER2–neu receptor | Negative | 53 (71.6%) | 21 (28.4%) | 0.19 |
Positive | 22 (84.6%) | 4 (15.4%) | ||
Triple negative breast cancer | No | 44 (86.3%) | 7 (13.7%) | 0.01a |
Yes | 31 (63.3%) | 18 (36.7%) |
Table 5 Univariable and multivariable logistic regression analysis for forkhead box P3-negative (reference) vs forkhead box P3-positive
Variables | Characteristics | Univariable analysis odds ratio (95%CI), P value | Multivariable analysis odds ratio (95%CI), P value |
IDO score | Low | Ref. | Ref. |
Medium | 1.91 (0.32-11.52), 0.50 | 2.32 (0.37-14.50), 0.37 | |
High | 6.97 (1.50-33.10), 0.01a | 5.90 (1.22-28.64), 0.03a | |
Triple negative breast cancer | No | Ref. | Ref. |
Yes | 3.65 (1.36-9.80), 0.01a | 2.80 (0.96-7.95), 0.05a |
- Citation: Asghar K, Loya A, Rana IA, Bakar MA, Farooq A, Tahseen M, Ishaq M, Masood I, Rashid MU. Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients. World J Clin Oncol 2020; 11(12): 1018-1028
- URL: https://www.wjgnet.com/2218-4333/full/v11/i12/1018.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i12.1018